Amid the war on obesity, a clear winner has emerged in a battle between two weight-loss injectables. Zepbound (tirzepatide), ...

David Ricks told a lunch audience at the Economic Club of Washington, D.C., that Zepbound could quickly become the most ...

Results from the head-to-head study showed treatment with Zepbound resulted in 47% greater relative weight loss than Wegovy, ...

Eli Lilly said patients taking its obesity drug Zepbound lost 47% more weight than those who were given Novo Nordisk's Wegovy ...

People taking the weight loss drug Zepbound experienced dramatically greater weight loss than competitor Wegovy in the first head-to-head trial.

Zepbound, a drug with the main active ingredient tirzepatide, was found to be more helpful in helping people lose weight than ...

The proposed buyout of contract drug manufacturer Catalent won’t raise competition concerns, the European Commission said.

Even as weight-loss drugs such as Wegovy and Zepbound explode in popularity, many Americans struggle to afford them.

Weight loss drugs such as Ozempic and Wegovy are increasingly popular among adults, who have flocked to the new medication as ...

The biotech disclosed Friday plans to terminate a Phase 2 study testing azelaprag with tirzepatide for weight loss following ...

Adults who take Zepbound lose more weight than those who take competitor weight loss drug Wegovy, according to new clinical ...

Zepbound, the new GLP-1 weight-loss drug from Eli Lilly & Co., has outperformed its main competitor, Wegovy, in a clinical ...